Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07459634 · ClinicalTrials.gov registry record · Phase 2
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Not yet
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT07459634 is a Phase 2 study that has not yet begun recruiting, run by Jazz Pharmaceuticals. The registered enrollment target is 50 participants.
The verdict
NCT07459634, a Phase 2 study, has not yet begun recruiting, sponsored by Jazz Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
Interventions
- DRUG Durvalumab
- DRUG Lurbinectedin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-06-12 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07459634
The ClinicalTrials.gov registry entry for NCT07459634 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT07459634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07459634 about?
NCT07459634 is a clinical study titled "A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC". The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
What is the current status of trial NCT07459634?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-06-12. Estimated completion is 2028-04-30.
What interventions are being tested in trial NCT07459634?
The interventions under investigation include: Durvalumab (DRUG), Lurbinectedin (DRUG).
Who is sponsoring clinical trial NCT07459634?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.